CME Event About Women’s Cancers – June 26, 2025
“The Right Treatment for Each Patient: Women’s Cancers and Personalized Therapies” is the title of the CME-accredited conference scheduled for June 26, 2025. The event will focus on the role of therapeutic innovation in the treatment of breast and ovarian cancer.
The conference is organized under the scientific direction of Dr. Antonio Febbraro, Medical Director of the UPMC Hillman Cancer Center Villa Maria Radiotherapy Center and Director of the Oncology Department at Casa di Cura Villa Maria.
Accredited by Agenas for the awarding of 4 CME credits, the course is open to a maximum of 50 participants, including medical doctors (from all specialties), pharmacists (hospital, community, and other sectors), biomedical laboratory and medical radiology technicians, psychologists (clinical and psychotherapists), nurses, and dietitians.
Course Objectives
The course aims to explore the role of therapeutic innovation in the treatment of breast and ovarian cancer, with a particular focus on recent advances in molecular diagnostics and the outcomes of clinical trials. The goal is to foster a shared reflection on the effectiveness of personalized therapies, made possible through patient selection based on molecular or genetic profiling. This approach allows for the identification of individuals who are more likely to respond positively to treatment, thereby improving clinical outcomes and reducing unnecessary or ineffective therapies.
Breast and Ovarian Cancer
Breast and ovarian cancers represent two oncological areas in which scientific innovation has led to some of the most significant advances, both in diagnostics and in therapy. The study of genetic mutations and molecular alterations underlying these malignancies has enabled the identification of specific targets involved in carcinogenesis, tumor cell proliferation, and metastasis. Based on these discoveries, innovative drugs have been developed that can selectively act on specific molecular targets.
At the same time, advances in immunological research have led to the identification of new mechanisms of action, such as immune checkpoints, paving the way for inhibitory immunomodulatory therapies capable of enhancing the immune response against cancer in a targeted manner.
An increasingly in-depth understanding of the molecular biology of cancer cells has made it possible to stratify tumors into biologically distinct subgroups, each associated with specific prognostic and therapeutic profiles. This has marked the transition from evidence-based medicine to a personalized medicine model, which integrates the molecular alterations of the tumor subgroup with the patient’s clinical characteristics to define tailored therapeutic strategies.
The adoption of this approach is now considered standard in the management of breast and ovarian cancers, with the goal of maximizing treatment effectiveness while minimizing toxicity.
CME Provider and Organizing Secretariat
BenEventi S.r.l. a socio unico
Via Clementina Perone, 39 - 82100 BENEVENTO
P.IVA 01758480626
Tel: 0824 50631
Mail: info@beneventi.eu
For more information and to register, visit the event page.